Articles tagged with Breast Cancer
A synthetic gene network implanted under the skin monitors blood calcium levels to detect four common types of cancer, triggering a visible mole when a threshold is exceeded. Early detection increases survival chances by up to 98%, significantly improving treatment outcomes.
Triple negative breast cancer brain metastases typically have lower numbers of immune cells, but those present are responsive to checkpoint inhibitor therapies. Researchers aim to increase immune cell presence and responsiveness to improve treatment outcomes.
A pre-clinical study has revealed that combining OX40 agonist antibody and GSK2366771 may enhance the immune system's ability to kill melanoma tumors deficient in PTEN. The combination appears to 'step on the gas', revving up T cells and providing extra power to more efficiently kill cancer cells.
A new BJS study found axillary ultrasound imaging to be less sensitive for detecting axillary metastatic lymph nodes in women with invasive lobular carcinoma compared to invasive ductal carcinoma. Women with invasive lobular carcinoma may benefit from axillary biopsies regardless of ultrasonographic appearance.
Researchers found tumors with PTEN loss are less likely to generate an immune response, suggesting PTEN levels can predict treatment outcome. The study's findings may improve personalized medicine for BRCA-deficient ovarian cancer patients.
St. Jude Children's Research Hospital investigators present research on cloud computing, exhausted T cells, breast cancer risk in childhood cancer survivors and clinical trial design for CAR-T therapy in solid tumors. The platform St. Jude Cloud provides unique analysis tools and visualizations of pediatric cancer genomics data.
Researchers identified RB1 gene mutations as a mechanism underlying acquired resistance to CDK 4/6 inhibitor treatment for HR-positive breast cancer. The study found that these mutations led to loss of RB1 function and consequently resistance to CDK 4/6 inhibitors in patients whose tumors progressed after treatment.
Researchers found that adding trastuzumab to chemotherapy regimen for women with uterine serous carcinoma significantly increased progression-free survival time, from an average of eight months to 12.6 months. The treatment showed promise in reducing tumor growth and improving overall survival.
A study by researchers at the National University of Singapore found that almost half of breast cancer patients experience cognitive decline during treatment, with symptoms persisting up to a year after. The study highlights the importance of early screening and management to improve quality of life for survivors.
Researchers have discovered a new class of drug that targets treatment-resistant cancers by inhibiting the action of enzyme CDK7. Early lab-based tests showed minimal side effects and successful suppression of tumour growth in various cancer types.
A large study of breast cancer patients found that radiotherapy and chemotherapy do not significantly increase the risk of heart disease. Good risk management in hospitals and short interval screenings may offset elevated risks. The study's findings are considered positive for treatment of breast cancer.
Researchers discovered that some cancers are genetically similar, despite originating from different organs, and grouped them into new subtypes. The study's findings support an additional cancer classification system, which could lead to improved treatment options for patients.
Researchers have discovered five previously unknown cancer subtypes among others, using a comprehensive analysis of 2,579 tumors from breast and gynecologic cancers. The study identifies shared and unique molecular features, clinically significant subtypes, and potential therapeutic targets.
A recent study analyzing breast tissue from 344 transmen found benign and malignant lesions in 48.3% of individuals. Invasive breast cancer was detected in just two samples, emphasizing the importance of thorough histopathological examination.
Researchers developed a surgical camera inspired by the morpho butterfly's eye to help surgeons detect cancerous tissue. The camera uses infrared signals to locate tumors and can be integrated with surgical goggles, making it more accessible and cost-effective than existing technologies.
A new study shows that a free web-based decision aid, BRECONDA, reduces decisional conflict and increases satisfaction with information among women considering breast reconstruction. The cost of the decision aid was estimated to be small compared to other healthcare interventions.
A recent study published in The Breast Journal found that only 1.5% of patients with microinvasive breast cancer had positive lymph nodes, suggesting that these tiny tumors rarely spread cancer to other areas. This discovery allows surgeons to select patients who may benefit from lymph node sampling, sparing others from the procedure.
The Cancer Genome Atlas project has identified 300 genes that drive tumor growth and found that just over half of tumors carry genetic mutations targetable by existing therapies. The research provides unprecedented understanding of cancer's genetic basis, enabling better-informed clinical trials and future treatments.
Researchers have developed a universal fluorescent probe that targets and stains cancer stem cells, a type of tumor-initiating cell. The probe, named TiY, demonstrates high selectivity towards these cells, which are believed to cause relapses after radiation and chemotherapy.
Researchers identify PFKFB4 enzyme as potent driver of breast cancer, offering new treatment possibilities. The study found that targeting this enzyme or SRC-3 can almost completely eliminate breast cancer recurrence and metastasis.
A new study finds that establishing a minimum recall rate for breast cancer screening programs can help balance the risk of missing invasive cancers and the cost of additional testing. The study analyzed data from the UK Breast Cancer Service Screening Program, finding that lower recall rates correlate with higher interval cancer rates.
Women with breast implants are more likely to have detectable cancers at a smaller size compared to those without implants. The study found that screening mammograms may be less effective in detecting cancers in breasts with implants.
Researchers have identified a specific sugar found on aggressive breast cancer cells that can be used as a biomarker to detect high-risk patients. This discovery aims to improve screening for early-stage breast cancer patients, reducing unnecessary treatments such as chemotherapy or radiation.
Scientists at Michigan State University have discovered a promising new drug that targets the c-Myc gene, which is linked to obesity and various cancers. The drug, I-BET-762, delays the development of existing cancers by inhibiting critical proteins involved in cancer cell growth.
The new instrument increases the sensitivity of optical mammography by up to 1000-fold, allowing for earlier detection of breast cancer. This advancement offers a safer and more gentle alternative to traditional X-ray imaging, which is often limited by patient age, weight, or other factors.
Breast cancer experts are urging men to participate in clinical trials to discover better treatment options. The research highlights the benefits of targeted treatments, such as reducing radical surgery and improving cosmetic results for men with breast cancer.
New results from IMPORT LOW trial show women treated with partial or reduced breast radiotherapy report fewer side-effects, including less change in breast appearance. The study found that over half of patients did not experience moderate or marked side-effects at any point.
A newly designed chimera could simultaneously decrease the expression of three growth factors that are over-expressed in some cancers, leading to cancer cell death. The molecule has potent anti-tumor activity and is non-toxic, simple to produce, and cost-effective compared to traditional treatment strategies.
A Cancer Research UK landmark study found that smoking remains a major preventable cause of cancer, accounting for 32,200 cases in men and 22,000 in women. Excess weight is also a significant risk factor, with over 22,800 cases attributed to being overweight or obese annually.
Researchers found that targeted drug treatment before surgery can safely treat women with aggressive tumours using breast-conserving surgery, sparing patients from extensive surgery. This approach resulted in fewer long-term side-effects and improved quality of life for a significant proportion of patients.
Women with small, low-grade tumors and a genetic profile at low risk of metastasis have only a 1.4% chance of locoregional recurrence within five years. Breast conservation surgery is as effective as mastectomy in reducing the risk of recurrence.
A new model predicts the extra risk of death for breast cancer patients and survivors, taking into account improved survival rates over time. The model could lead to lower life insurance premiums and increased transparency for patients.
Two new studies show that women with 'triple negative' or HER2 positive breast cancers who respond well to chemotherapy before surgery have a very low risk of having cancer cells in their lymph nodes. Chemotherapy can safely reduce or avoid lymph node surgery for these patients, potentially reducing long-term side effects.
The average size of breast tumors decreased dramatically following the introduction of screening in the 1980s and 1990s. However, a recent study found that this trend has reversed since 2001, with a slight increase in tumor size. Women with smaller tumors at diagnosis tend to have better survival rates.
Researchers developed a new approach using biodegradable gels containing immune-stimulating drugs to deliver immunotherapy directly to the surgical site, preventing tumor recurrence and metastasis. The method showed promising results in mice with breast, lung, and melanoma tumors, offering hope for improving cancer treatment outcomes.
Researchers at the University of Illinois Chicago are developing a small drug molecule that can block JAG1, a cell surface protein found on triple-negative breast cancer cells. The new therapy aims to reduce tumor growth and metastasis, with fewer side effects than aggressive chemotherapy or radiation.
The researchers used cryo-electron microscopy to provide a high-resolution view of the NuA4/TIP60 complex. The structure reveals that Tra1/TRRAP serves as a scaffold for NuA4/TIP60 assembly and that human TRRAP mutations are largely centered on interaction surfaces mediating this assembly.
Women with BRCA1 mutations who undergo double mastectomy have lower breast cancer-specific survival, compared to those under surveillance. For BRCA2 mutation carriers, there is no difference in the chances of dying from breast cancer between mastectomy and surveillance.
A study found that patients with ductal carcinoma in situ (DCIS) who are post-menopausal or estrogen receptor positive have a low risk of recurrence. Treatment with breast-conserving surgery and radiotherapy leads to very low rates of recurrence. The research also identifies clues for tailoring treatments to individual patients.
A Brazilian study found a strong association between vitamin D insufficiency and metabolic syndrome (MetS) in postmenopausal women. The researchers detected MetS in 57.8% of the women with vitamin D insufficiency or deficiency, while only 39.8% had sufficient levels.
Researchers found that polygenic risk scores, which were originally developed to predict first breast cancer risk, can also quantify the risk of a second breast cancer in BRCA carriers. This technology has been shown to be effective in predicting the risk of a second breast cancer in women with high-risk BRCA gene mutations.
Immunotherapy has shown promising results in treating metastatic breast cancer, with a median progression-free survival of 33 months and median overall survival of 82 months. The treatment has been found to improve PFS and OS in both luminal and non-luminal subtypes, offering new hope for patients with this incurable disease.
A clinical trial found that HRD-positive triple negative breast cancer patients respond well to standard AC chemotherapy, with better disease-free survival rates. The study used preserved tissue samples from nearly two decades ago and demonstrated the value of banking tissue for future research.
New research finds a positive link between BMI and DNA damage in BRCA mutation carriers. Obesity is associated with higher levels of gamma-H2AX foci, indicating increased DNA damage.
Researchers have discovered a novel gene, EDC4, involved in familial breast cancer. The study found that mutations in EDC4 impair DNA repair mechanisms, making cells sensitive to PARP inhibitors.
Researchers at OHSU discovered the tumor microenvironment's impact on breast cancer cell growth and response to treatment. The study found that targeting resistance factors from the microenvironment could improve clinical outcomes for patients treated with HER2-targeted drugs.
Researchers found that obesity and inflammation promote resistance to anti-VEGF therapy in breast cancer. Blocking specific molecules like IL-6 or FGF-2 may overcome this resistance and improve treatment response.
A new imaging technology has been developed to grade tumour biopsies, eliminating human subjectivity and variability. The Digistain method uses mid-infrared light to map out chemical changes that signal cancer onset, providing a reliable indicator of disease progression.
Researchers at Lund University have developed a new drug that transforms aggressive breast cancer into hormone-sensitive luminal breast cancers, making them responsive to conventional hormone therapy.
Researchers have identified 110 genes linked to an increased risk of breast cancer, including 32 genes related to survival rates. The study uses a genetic technique to analyze DNA regions and identify specific genes involved in raising a woman's risk.
Researchers at Wake Forest Baptist Medical Center have developed a fluorescing nanoparticle that can find tumors and generate heat to destroy cancer cells. The nanoparticles, called Hybrid Donor-Acceptor Polymer Particles (H-DAPPs), successfully localized and killed breast cancer in mice, showing potential for future human trials.
A new study found that nearly half of women with breast cancer who should undergo genetic testing did not receive it. Genetic counselors were underutilized, with only half of those in the high-risk group receiving counseling before surgery.
The new guideline recommends hypofractionated whole breast irradiation (WBI) for most breast cancer patients, regardless of age or tumor stage. This accelerated treatment offers a more convenient and lower-cost option without compromising cancer control or side effects.
A multi-arm, placebo-controlled study showed that ACE inhibitors and beta blockers can significantly offset the risk of heart problems for patients with HER2-positive breast cancer. The data demonstrated a significant reduction in cardiotoxicity for patients on these medications who received doxorubicin before Herceptin.
Researchers found that nonwhite women were diagnosed at younger ages and with more advanced cancers than white women. The current guidelines may not account for racial differences, leading to delayed diagnosis and potentially harmful outcomes.
A higher proportion of nonwhite patients were diagnosed at younger than 50 years of age compared to white patients, underscoring the need for personalized screening guidelines. The study's findings challenge the use of single age-based screening guidelines that do not account for race.
Researchers identified genetic patterns in primary and matched metastatic cancers, finding that cells often break away as a collection rather than spreading as a single cell. This insight may lead to better treatments or approaches to prevent its spread at the onset.
Women living in US territories receive less comprehensive breast cancer care compared to their continental US counterparts, including delayed surgical treatments and radiation therapy. The study highlights the importance of addressing healthcare disparities in these underserved populations.
Researchers found elevated mir-24-3p in breast cancer patients destined to metastasize despite best available therapy. High expression of mir-24-3p correlated with poor survival rate and specific gene expression signature in TCGA.
A new blood test detects circulating tumour DNA to predict if the breast cancer drug palbociclib is working, allowing for earlier treatment adjustments. The test was found to be effective in identifying patients who are not responding well to the treatment.